MX2023006688A - Eliminacion genomica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables. - Google Patents

Eliminacion genomica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables.

Info

Publication number
MX2023006688A
MX2023006688A MX2023006688A MX2023006688A MX2023006688A MX 2023006688 A MX2023006688 A MX 2023006688A MX 2023006688 A MX2023006688 A MX 2023006688A MX 2023006688 A MX2023006688 A MX 2023006688A MX 2023006688 A MX2023006688 A MX 2023006688A
Authority
MX
Mexico
Prior art keywords
cell lines
stable cell
swine fever
african swine
allowing efficient
Prior art date
Application number
MX2023006688A
Other languages
English (en)
Inventor
Manuel V Borca
Douglas P Gladue
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of MX2023006688A publication Critical patent/MX2023006688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se ofrecen detalles sobre la construcción de una vacuna viva atenuada recombinante de un virus de la peste porcina africana (ASFV) para la prevención de la ASF causada por diversas cepas del ASFV, tal como el aislado altamente virulento Georgia 2007 ("ASFV G"). Una vacuna ilustrativa comprende una eliminación de múltiples genes que permite el crecimiento a escala industrial en estirpes celulares estables.
MX2023006688A 2020-12-22 2021-03-25 Eliminacion genomica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables. MX2023006688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/130,814 US11766476B2 (en) 2020-12-22 2020-12-22 Genomic deletion in African swine fever vaccine allowing efficient growth in stable cell lines
PCT/US2021/024124 WO2022139861A1 (en) 2020-12-22 2021-03-25 Genomic deletion in african swine fever vaccine allowing efficient growth in stable cell lines

Publications (1)

Publication Number Publication Date
MX2023006688A true MX2023006688A (es) 2023-06-19

Family

ID=82023892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006688A MX2023006688A (es) 2020-12-22 2021-03-25 Eliminacion genomica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables.

Country Status (12)

Country Link
US (1) US11766476B2 (es)
EP (1) EP4267727A1 (es)
JP (1) JP2024500225A (es)
KR (1) KR20230136600A (es)
CN (1) CN116670153A (es)
AU (1) AU2021410544A1 (es)
BR (1) BR112023012529A2 (es)
CA (1) CA3202140A1 (es)
CL (1) CL2023001826A1 (es)
CO (1) CO2023007528A2 (es)
MX (1) MX2023006688A (es)
WO (1) WO2022139861A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958782B (zh) * 2022-03-16 2023-03-24 中国农业科学院兰州兽医研究所 一种iptg诱导性缺失d1133l基因的非洲猪瘟病毒减毒株及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US11007263B2 (en) * 2019-09-24 2021-05-18 The United States Of America, As Represented By The Secretary Of Agriculture Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L
WO2022090131A1 (en) * 2020-10-26 2022-05-05 Consejo Superior De Investigaciones Científicas Recombinant african swine fever virus as live attenuated vaccine against african swine fever

Also Published As

Publication number Publication date
CN116670153A (zh) 2023-08-29
AU2021410544A1 (en) 2023-07-20
JP2024500225A (ja) 2024-01-05
WO2022139861A1 (en) 2022-06-30
BR112023012529A2 (pt) 2023-10-03
US11766476B2 (en) 2023-09-26
US20220193217A1 (en) 2022-06-23
CO2023007528A2 (es) 2023-10-30
EP4267727A1 (en) 2023-11-01
CA3202140A1 (en) 2022-06-30
CL2023001826A1 (es) 2023-11-17
KR20230136600A (ko) 2023-09-26

Similar Documents

Publication Publication Date Title
MX2022003435A (es) Desarrollo de una vacuna novedosa atenuada viva contra la peste porcina africana basada en la eliminacion del gen i177l.
PH12018502684A1 (en) A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate
Skinner et al. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
IL276210B2 (en) MERS-COV vaccine
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX2021014525A (es) Adenovirus modificados.
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
CL2012000452A1 (es) Acido nucleico infeccioso de virus torque teno porcino (pttv), que comprende secuencia que codifica un pttv infeccioso con una secuencia genomica de pttv 1a-va; acido nucleico, plasmido y celula hospedera que la comprenden; pttv infeccioso no virulento; vacuna.
MX2023006688A (es) Eliminacion genomica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables.
PH12019501320A1 (en) Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
MX2023002008A (es) Vectores de adenovirus y metodos para el uso de los mismos.
FI3244920T3 (fi) Suu- ja sorkkatautirokote
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
PH12017500216B1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
RU2012119494A (ru) Выделение вируса, родственного парвовирусу-2 собак, от енота
DK1567653T3 (da) Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
MX2022006546A (es) Reovirus aviar atenuado cepas 94826 c140 y 96139 c140.
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
MY169061A (en) Modified marek's disease virus, and vaccines made therefrom
MX2023012219A (es) Vacuna contra el virus de la pseudorrabia.
AR124849A1 (es) Vacuna para mycoplasma bovis
MX2023005618A (es) Plataforma de levadura para la produccion de vacunas.